Cannabinoide in der Palliativmedizin

Summary

Die Diskussion um Cannabinoide wird emotional geführt, oft werden die medizinische Anwendung und der nicht medizinische Konsum vermischt. Zusammen mit Vorurteilen gegenüber der Substanzgruppe und einer abwertenden Wortwahl führt das zum schambesetzten Umgang mit diesem Thema bei betroffenen Patienten in der Palliativsituation und zur Verunsicherung der Behandelnden.

Der Artikel fasst die seit Januar 2017 geltenden gesetzlichen Rahmenbedingungen zusammen, erläutert die verfügbaren Produkte und deren Verordnungsmodalitäten. Basierend auf der aktuellen Studienlage werden die möglichen Einsatzgebiete mit palliativmedizinischem Fokus erörtert.

Keywords

Cannabinoide - Dronabinol - Nabilon - Cannabidiol - Palliativmedizin

• Literatur

• 1 Tai SY, Lee CY, Wu CY. et al. Symptom severity of patients with advanced cancer in palliative care unit: longitudinal assessments of symptoms improvement. BMC palliative care 2016; 15: 32
• 2 Ford BM, Tai S, Fantegrossi WE. et al. Synthetic pot: not your grandfather’s marijuana. Trends Pharmacol Sci 2017; 38 (03) 257-276
• 3 Cressey D. The cannabis experiment. Nature 2015; 524 7565 280-283
• 4 Kilmer B. Recreational cannabis – minimizing the health risks from legalization. N Engl J Med 2017; 376 (08) 705-707
• 5 Zhang MW, Ho RC. The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy. J Addict 2015;
• 6 Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007; 4 (08) 1664-1677
• 7 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313 (24) 2456-2473
• 8 Müller-Vahl KG. F. Medizinisches Cannabis: Die wichtigsten Änderungen. Dtsch Arztebl. 2017; 114 (08) A352-356
• 9 Hua T, Vemuri K, Pu M. et al. Crystal structure of the human cannabinoid receptor CB1. Cell 2016; 167 (03) 750-762.e14
• 10 Zajicek JP, Hobart JC, Slade A. et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83 (11) 1125-1132
• 11 Jawahar R, Oh U, Yang S. et al. A systematic review of pharmacological pain management in multiple sclerosis. Drugs 2013; 73 (15) 1711-1722
• 12 Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109 (29/30) 495-501
• 13 Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012; 10 (04) 487-492
• 14 Hernandez SL, Sheyner I, Stover KT. et al. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care 2015; 32 (01) 5-7
• 15 May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res 2016; 8: 49-55
• 16 Benze G, Geyer A, Alt-Epping B. et al. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients: a systematic review]. Schmerz 2012; 26 (05) 481-499
• 17 Smith LA, Azariah F, Lavender VT. et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; (11) Cd009464
• 18 Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV / AIDS. Cochrane Database Syst Rev 2013; (04) Cd005175
• 19 Beal JE, Olson R, Laubenstein L. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (02) 89-97
• 20 Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014; 6 (01/02) 24-30
• 21 Brisbois TD, de Kock IH, Watanabe SM. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22 (09) 2086-2093
• 22 de Vries M, van Rijckevorsel DC, Wilder-Smith OH. et al. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opin Pharmacother 2014; 15 (11) 1525-1534
• 23 Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain 2013; 29 (02) 162-171
• 24 Portenoy RK, Ganae-Motan ED, Allende S. et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012; 13 (05) 438-449
• 25 Johnson JR, Burnell-Nugent M, Lossignol D. et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39 (02) 167-179
• 26 Carter GT, Flanagan AM, Earleywine M. et al. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care 2011; 28 (05) 297-303
• 27 Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12 (06) 436-444
• 28 Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol 2016; 23 (02) S8-S14
• 29 Davis MP. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. J Natl Compr Canc Netw 2016; 14 (07) 915-922
• 30 Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6 (01) 35-42
• 31 Maida V, Daeninck PJ. A user’s guide to cannabinoid therapies in oncology. Curr Oncol 2016; 23 (06) 398-406
• 32 Mucke M, Carter C, Cuhls H. et al. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz 2016; 30 (01) 25-36